Advertisement

Early detection with MRI of incomplete treatment of spine metastases after percutaneous cryoablation

  • Guillaume GravelEmail author
  • Lambros Tselikas
  • Benjamin Moulin
  • Steven Yevich
  • Eric Baudin
  • Antoine Hakime
  • Salma Moalla
  • Fadila Mihoubi
  • Corinne Balleyguier
  • Thierry de Baere
  • Frederic Deschamps
Vascular-Interventional
  • 16 Downloads

Abstract

Objectives

To evaluate post-ablation MRI for the detection of incompletely treated spinal osseous metastases (SOM) after cryoablation and to propose a post-ablation imaging classification.

Methods

After IRB consent, all patients treated with cryoablation of SOM between 2011 and 2017 having at least 1-year minimum follow-up and a spine MRI within 4 months after cryoablation were retrospectively included. A classification of MRI images into four types was set up. The primary endpoint of our study was to assess the diagnostic performance of the post-ablation MRI. The secondary endpoints were the 1-year complete treatment rate (CTR) and complications.

Results

Fifty-four SOMs in 39 patients were evaluated. Post-ablation MRI was performed with a median delay of 25 days after cryoablation. Images were evaluated by two independent readers according to the pre-established image classification. Sensitivity and specificity for the detection of residual tumor were 77.3% (95%CI = 62.2–88.5) and 85.9% (95%CI = 75.0–93.4), respectively. Types I, II, III, and IV of the classification were associated with a 1-year complete treatment in 100%, 83.3%, 35.7%, and 10% of cases, respectively. The 1-year CTR was 59.3% for all 54 metastases, and 95.8% for metastases measuring less than 25 mm and at least 2 mm or more away from the spinal canal. Two grade 3 and two grade 2 adverse events according to the CTCAE were reported.

Conclusions

MRI after cryoablation is useful for the evaluation of the ablation efficacy. The classification of post-cryoablation MRI provides reliable clues for the prediction of complete treatment at 1 year.

Key Points

• MRI performed 25 days after cryoablation is useful to evaluate the efficacy.

• The proposed classification provides a reliable clue for complete cryoablation.

• Percutaneous cryoablation of spinal metastases is highly effective for lesions less than 25 mm in diameter and of at least 2 mm away from the spinal canal.

Keywords

Cryotherapy Neoplasm metastasis Spine Magnetic resonance imaging 

Abbreviations

CTR

Complete treatment rate

PMMA

Polymethylmethacrylate

SOM

Spinal osseous metastases

SBRT

Stereotactic body radiotherapy

Notes

Funding

The authors state that this work has not received any funding.

Compliance with ethical standards

Guarantor

The scientific guarantor of this publication is Dr. Frederic Deschamps.

Conflict of interest

The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Informed consent

Written informed consent was waived by the Institutional Review Board.

Ethical approval

Institutional Review Board approval was obtained.

Methodology

• retrospective

• diagnostic study

• performed at one institution

References

  1. 1.
    Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sCrossRefGoogle Scholar
  2. 2.
    Fornasier VL, Horne JG (1975) Metastases to the vertebral column. Cancer 36:590–594CrossRefGoogle Scholar
  3. 3.
    Deschamps F, Farouil G, de Baere T (2014) Percutaneous ablation of bone tumors. Diagn Interv Imaging 95:659–663CrossRefGoogle Scholar
  4. 4.
    Munk PL, Murphy KJ, Gangi A, Liu DM (2011) Fire and ice: percutaneous ablative therapies and cement injection in management of metastatic disease of the spine. Semin Musculoskelet Radiol 15:125–134CrossRefGoogle Scholar
  5. 5.
    Deschamps F, Farouil G, Ternes N et al (2014) Thermal ablation techniques: a curative treatment of bone metastases in selected patients? Eur Radiol 24:1971–1980CrossRefGoogle Scholar
  6. 6.
    Gravel G, Leboulleux S, Tselikas L et al (2018) Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma. Endocrine 59:547–554CrossRefGoogle Scholar
  7. 7.
    Yang H-L, Liu T, Wang X-M et al (2011) Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604–2617CrossRefGoogle Scholar
  8. 8.
    Vanel D, Bittoun J, Tardivon A (1998) MRI of bone metastases. Eur Radiol 8:1345–1351CrossRefGoogle Scholar
  9. 9.
    Lecouvet FE, Larbi A, Pasoglou V et al (2013) MRI for response assessment in metastatic bone disease. Eur Radiol 23:1986–1997CrossRefGoogle Scholar
  10. 10.
    National Cancer Institute (2018) Common Terminology Criteria for Adverse Events (CTCAE). Available via https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 20 Sep 2018
  11. 11.
    Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458CrossRefGoogle Scholar
  12. 12.
    Cohen J (1968) Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 70:213–220CrossRefGoogle Scholar
  13. 13.
    Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefGoogle Scholar
  14. 14.
    Buhmann Kirchhoff S, Becker C, Duerr HR et al (2009) Detection of osseous metastases of the spine: comparison of high resolution multi-detector-CT with MRI. Eur J Radiol 69:567–573CrossRefGoogle Scholar
  15. 15.
    Thibault I, Chang EL, Sheehan J et al (2015) Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. Lancet Oncol 16:e595–e603CrossRefGoogle Scholar
  16. 16.
    Constantinidou A, Martin A, Sharma B, Johnston SRD (2011) Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol 22:307–314CrossRefGoogle Scholar
  17. 17.
    De Giorgi U, Mego M, Rohren EM et al (2010) 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 51:1213–1218CrossRefGoogle Scholar
  18. 18.
    Deandreis D, Leboulleux S, Dromain C et al (2011) Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology 258:270–276CrossRefGoogle Scholar
  19. 19.
    Tomasian A, Wallace A, Northrup B et al (2016) Spine cryoablation: pain palliation and local tumor control for vertebral metastases. AJNR Am J Neuroradiol 37:189–195CrossRefGoogle Scholar
  20. 20.
    de Baere T, Elias D, Dromain C et al (2000) Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 175:1619–1625CrossRefGoogle Scholar
  21. 21.
    de Baère T, Aupérin A, Deschamps F et al (2015) Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 26:987–991CrossRefGoogle Scholar
  22. 22.
    Vidoni A, Grainger M, James S (2018) Experience of neuroprotective air injection during radiofrequency ablation (RFA) of spinal osteoid osteoma. Eur Radiol 10:4146–415023CrossRefGoogle Scholar
  23. 23.
    Wang XS, Rhines LD, Shiu AS et al (2012) Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol 13:395–402CrossRefGoogle Scholar
  24. 24.
    Yamada Y, Bilsky MH, Lovelock DM et al (2008) High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 71:484–490CrossRefGoogle Scholar
  25. 25.
    Boehling NS, Grosshans DR, Allen PK et al (2012) Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine 16:379–386CrossRefGoogle Scholar
  26. 26.
    Rose PS, Laufer I, Boland PJ et al (2009) Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol 27:5075–5079CrossRefGoogle Scholar
  27. 27.
    Myrehaug S, Sahgal A, Hayashi M et al (2017) Reirradiation spine stereotactic body radiation therapy for spinal metastases: systematic review. J Neurosurg Spine 27:428–435CrossRefGoogle Scholar

Copyright information

© European Society of Radiology 2019

Authors and Affiliations

  • Guillaume Gravel
    • 1
    Email author
  • Lambros Tselikas
    • 1
  • Benjamin Moulin
    • 1
  • Steven Yevich
    • 1
  • Eric Baudin
    • 2
  • Antoine Hakime
    • 1
  • Salma Moalla
    • 1
    • 3
  • Fadila Mihoubi
    • 3
  • Corinne Balleyguier
    • 3
  • Thierry de Baere
    • 1
  • Frederic Deschamps
    • 1
  1. 1.Department of Interventional RadiologyGustave Roussy Cancer CenterVillejuifFrance
  2. 2.Department of Nuclear Medicine and Endocrine OncologyGustave Roussy Cancer CenterVillejuifFrance
  3. 3.Department of Diagnostic RadiologyGustave Roussy Cancer CenterVillejuifFrance

Personalised recommendations